Skip to main content

Press releases | May 2, 2023

Fried Frank acted as counsel to BofA Securities and Centerview Partners as financial advisors to Iveric Bio in the $5.9 billion acquisition by Astellas Pharma. Iveric Bio focuses on the discovery and development of novel treatments in the field of ophthalmology. Astellas researches and produces innovative drugs for diseases with high unmet medical need by identifying unique combinations of biology and therapeutic modality/technology from multiple perspectives. 

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.